French multinational pharmaceutical and healthcare firm Sanofi has completed a £1.4 billion buy-in for its pension scheme.

Sanofi Pension Scheme has completed a £1.4bn (€1.7bn) buy-in securing the benefits of 4,900 retirees and 5,600 deferred ...

Legal & General Assurance Society Limited (“Legal & General”) has completed a £1.4 billion buy-in with the Sanofi Pension Scheme (“the Scheme”), securing the benefits of 4,900 retirees and 5,600 ...

Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) saw its price target increased by Leerink Partners from €113.00 to €120.00, while the firm maintained an Outperform rating on the company's shares. Currently ...

2. Mr. J. M. Georges, Director, Industrial Pharma Intercontinental of the sanofi-aventis Group and Mr. F. X. Duhalde, Director - Finance & Administration of the sanofi-aventis Group, have been ...

Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t ...

Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...

The City of Greensboro, North Carolina, which provides public safety, emergency, and health services to over 300,000 residents and spends millions annually on insulin medications, filed a lawsuit last ...

Sanofi India Limited, (Previously known as Aventis Pharma Limited) was incorporated in May, 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11 ...

The bulk annuity transaction for the scheme has fully secured the benefits of 4,900 retirees and 5,600 deferred members. The ...

Hoechst and Rhône-Poulenc Rorer were the two companies that merged to form Aventis. Despite Sanofi-Synthélabo’s size, the company found itself forced to partner with larger pharmaceutical ...

The defendants listed include the drug manufacturers Eli Lilly, Novo Nordisk and Sanofi Aventis U.S., and PBM ... are the key counterweight to pharmaceutical companies' otherwise unchecked ...